![simple syn simple syn](https://www.simplesyn.net/Media/Default/images/logos/outlook2013.png)
Implications for Practiceīecause the PREMM5 tool is free, quick, and simple to use, it could help expand the reach of Lynch syndrome testing, noted Syngal. PREMM5 demonstrated it could effectively discriminate between carriers and non-carriers of the Lynch syndrome genes. The model was then validated in a cohort of 1,058 patients with colorectal cancer who were recruited to an institutional sample registry at Dana-Farber. The test order forms provided information on the individuals' age at genetic testing, sex, personal, and family cancer histories-including age at diagnosis-and Syngal's team concurrently analyzed the germline testing results.īy correlating these two sets of data, the researchers produced an algorithm to predict the likelihood a person had inherited a mutation in one of the five genes. PREMM5 was developed by analyzing data from 18,734 patients who underwent germline genetic testing for the Lynch mutations, including numerous healthy patients who did not have cancer but had relatives with cancers. Lynch syndrome is also associated with elevated risk of cancers of the pancreas, small intestine, bile ducts, urinary tract, brain, and oil glands in the skin. Someone with Lynch syndrome may have as much as an 80 percent lifetime risk of colorectal cancer and women have a 40-60 percent lifetime risk of developing endometrial cancer.
![simple syn simple syn](https://basementbakehouse.com/wp-content/uploads/2016/12/DSC_0041.png)
The researchers recommend that an individual whose risk is 2.5 percent or greater, as identified by PREMM5 model, be referred for genetic counseling and testing to determine if he or she has a Lynch syndrome mutation. From the answers to these questions, which take less than 2 minutes to complete, the model calculates the probability that the person carries a mutation in any of the five Lynch syndrome genes in their germline-reproductive cells inherited from parents. The 10 questions in PREMM5 are about the individual's sex, age, personal history of cancer, and history of certain cancers among relatives. “Most Lynch syndrome mutation carriers aren't aware of it because genetic testing rates and knowledge about the condition are much lower than for other cancer-predisposing genes like BRCA1 and BRCA2, which are associated with breast and ovarian cancer,” said Sapna Syngal, MD, MPH, Director of Research at the Center for Cancer Genetics and Prevention in the Population Sciences Division at Dana-Farber, and senior author of the report. The new online model, developed by Dana-Farber researchers and doctors, is called PREMM5, and enables people to quickly assess their likelihood of carrying one of these genes associated with Lynch syndrome ( J Clin Oncol 2017 doi:10.1200/JCO.20). The five genes are MLH1, MSH2, MSH6, PMS2, and EPCAM. Mutations in these so-called “mismatch repair” genes impair cells' ability to heal breaks in their DNA, making genetically damaged cells prone to abnormal growth and the development of cancer. An online assessment tool developed at Dana-Farber Cancer Institute, Boston, can help rapidly identify people who should undergo genetic testing for Lynch syndrome, an inherited disorder that greatly increases the lifetime risk of colorectal, endometrial, ovarian, stomach, and other cancers.Īn estimated 1 in 279 individuals-nearly a million people in the U.S.-carry a mutation in one of five different genes that can cause Lynch syndrome.